Goldman Sachs Group Inc Albireo Pharma, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$18.01 - $23.78 $303,810 - $401,144	-16,869 Reduced 57.04%	12,706 $274,000
Q4 2022 Feb 13, 2023	SELL	$18.01 - $23.78 $303,810 - $401,144	-16,869 Reduced 57.04%	12,706 $274,000
Q3 2022 May 14, 2024	SELL	$16.32 - $26.37 $768,900 - $1.24 Million	-47,114 Reduced 61.44%	29,575 $573,000
Q3 2022 Nov 10, 2022	SELL	$16.32 - $26.37 $768,900 - $1.24 Million	-47,114 Reduced 61.44%	29,575 $572,000
Q2 2022 May 14, 2024	BUY	$18.54 - $37.29 $1.42 Million - $2.86 Million	76,689 New	76,689 $0
Q2 2022 Aug 15, 2022	BUY	$18.54 - $37.29 $618,531 - $1.24 Million	33,362 Added 77.0%	76,689 $1.52 Million
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $3.07 Million - $4.32 Million	-128,140 Reduced 74.73%	43,327 $1.29 Million
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $337,980 - $499,075	15,950 Added 10.26%	171,467 $3.99 Million
Q3 2021 Nov 10, 2021	BUY	$27.36 - $35.98 $4.25 Million - $5.6 Million	155,517 New	155,517 $4.85 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.